Cargando…

Identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the African trypanosome

Trypanosoma brucei are unicellular parasites endemic to Sub-Saharan Africa that cause fatal disease in humans and animals. Infection with these parasites is caused by the bite of the tsetse fly vector, and parasites living extracellularly in the blood of infected animals evade the host immune system...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Madison Elle, Naudzius, Eleanor Mary, Diaz, Savanah Jessica, Wismar, Theodore William, Martchenko Shilman, Mikhail, Schulz, Danae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094864/
https://www.ncbi.nlm.nih.gov/pubmed/32168320
http://dx.doi.org/10.1371/journal.pntd.0007790
_version_ 1783510548747386880
author Walsh, Madison Elle
Naudzius, Eleanor Mary
Diaz, Savanah Jessica
Wismar, Theodore William
Martchenko Shilman, Mikhail
Schulz, Danae
author_facet Walsh, Madison Elle
Naudzius, Eleanor Mary
Diaz, Savanah Jessica
Wismar, Theodore William
Martchenko Shilman, Mikhail
Schulz, Danae
author_sort Walsh, Madison Elle
collection PubMed
description Trypanosoma brucei are unicellular parasites endemic to Sub-Saharan Africa that cause fatal disease in humans and animals. Infection with these parasites is caused by the bite of the tsetse fly vector, and parasites living extracellularly in the blood of infected animals evade the host immune system through antigenic variation. Existing drugs for Human and Animal African Trypanosomiasis are difficult to administer and can have serious side effects. Resistance to some drugs is also increasing, creating an urgent need for alternative trypanosomiasis therapeutics. We screened a library of 1,585 U.S. or foreign-approved drugs and identified 154 compounds that inhibit trypanosome growth. As all of these compounds have already undergone testing for human toxicity, they represent good candidates for repurposing as trypanosome therapeutics. In addition to identifying drugs that inhibit trypanosome growth, we wished to identify small molecules that can induce bloodstream form parasites to differentiate into forms adapted for the insect vector. These insect stage parasites lack the immune evasion mechanisms prevalent in bloodstream forms, making them vulnerable to the host immune system. To identify drugs that increase transcript levels of an invariant, insect-stage specific surface protein called procyclin, we engineered bloodstream reporter parasites that express Green Fluorescent Protein (GFP) following induction or stabilization of the procyclin transcript. Using these bloodstream reporter strains in combination with automated flow cytometry, we identified eflornithine, spironolactone, and phenothiazine as small molecules that increase abundance of procyclin transcript. Both eflornithine and spironolactone also affect transcript levels for a subset of differentiation associated genes. While we failed to identify compounds that increase levels of procyclin protein on the cell surface, this study is proof of principle that these fluorescent reporter parasites represent a useful tool for future small molecule or genetic screens aimed at identifying molecules or processes that initiate remodeling of the parasite surface during life cycle stage transitions.
format Online
Article
Text
id pubmed-7094864
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-70948642020-04-03 Identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the African trypanosome Walsh, Madison Elle Naudzius, Eleanor Mary Diaz, Savanah Jessica Wismar, Theodore William Martchenko Shilman, Mikhail Schulz, Danae PLoS Negl Trop Dis Research Article Trypanosoma brucei are unicellular parasites endemic to Sub-Saharan Africa that cause fatal disease in humans and animals. Infection with these parasites is caused by the bite of the tsetse fly vector, and parasites living extracellularly in the blood of infected animals evade the host immune system through antigenic variation. Existing drugs for Human and Animal African Trypanosomiasis are difficult to administer and can have serious side effects. Resistance to some drugs is also increasing, creating an urgent need for alternative trypanosomiasis therapeutics. We screened a library of 1,585 U.S. or foreign-approved drugs and identified 154 compounds that inhibit trypanosome growth. As all of these compounds have already undergone testing for human toxicity, they represent good candidates for repurposing as trypanosome therapeutics. In addition to identifying drugs that inhibit trypanosome growth, we wished to identify small molecules that can induce bloodstream form parasites to differentiate into forms adapted for the insect vector. These insect stage parasites lack the immune evasion mechanisms prevalent in bloodstream forms, making them vulnerable to the host immune system. To identify drugs that increase transcript levels of an invariant, insect-stage specific surface protein called procyclin, we engineered bloodstream reporter parasites that express Green Fluorescent Protein (GFP) following induction or stabilization of the procyclin transcript. Using these bloodstream reporter strains in combination with automated flow cytometry, we identified eflornithine, spironolactone, and phenothiazine as small molecules that increase abundance of procyclin transcript. Both eflornithine and spironolactone also affect transcript levels for a subset of differentiation associated genes. While we failed to identify compounds that increase levels of procyclin protein on the cell surface, this study is proof of principle that these fluorescent reporter parasites represent a useful tool for future small molecule or genetic screens aimed at identifying molecules or processes that initiate remodeling of the parasite surface during life cycle stage transitions. Public Library of Science 2020-03-13 /pmc/articles/PMC7094864/ /pubmed/32168320 http://dx.doi.org/10.1371/journal.pntd.0007790 Text en © 2020 Walsh et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Walsh, Madison Elle
Naudzius, Eleanor Mary
Diaz, Savanah Jessica
Wismar, Theodore William
Martchenko Shilman, Mikhail
Schulz, Danae
Identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the African trypanosome
title Identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the African trypanosome
title_full Identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the African trypanosome
title_fullStr Identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the African trypanosome
title_full_unstemmed Identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the African trypanosome
title_short Identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the African trypanosome
title_sort identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the african trypanosome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094864/
https://www.ncbi.nlm.nih.gov/pubmed/32168320
http://dx.doi.org/10.1371/journal.pntd.0007790
work_keys_str_mv AT walshmadisonelle identificationofclinicallyapprovedsmallmoleculesthatinhibitgrowthandaffecttranscriptlevelsofdevelopmentallyregulatedgenesintheafricantrypanosome
AT naudziuseleanormary identificationofclinicallyapprovedsmallmoleculesthatinhibitgrowthandaffecttranscriptlevelsofdevelopmentallyregulatedgenesintheafricantrypanosome
AT diazsavanahjessica identificationofclinicallyapprovedsmallmoleculesthatinhibitgrowthandaffecttranscriptlevelsofdevelopmentallyregulatedgenesintheafricantrypanosome
AT wismartheodorewilliam identificationofclinicallyapprovedsmallmoleculesthatinhibitgrowthandaffecttranscriptlevelsofdevelopmentallyregulatedgenesintheafricantrypanosome
AT martchenkoshilmanmikhail identificationofclinicallyapprovedsmallmoleculesthatinhibitgrowthandaffecttranscriptlevelsofdevelopmentallyregulatedgenesintheafricantrypanosome
AT schulzdanae identificationofclinicallyapprovedsmallmoleculesthatinhibitgrowthandaffecttranscriptlevelsofdevelopmentallyregulatedgenesintheafricantrypanosome